Who are Activated CIK's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IL-2 pre-treated CD19 cells, Licartin and CIK, TIL + IL2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/activated-cik.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Activated CIK — Competitive Intelligence Brief

Activated CIK (Activated CIK) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adoptive cell therapy; ex vivo expanded immune cells. Area: Oncology.

phase 2 Adoptive cell therapy; ex vivo expanded immune cells Oncology Biologic Live · refreshed every 30 min

Target snapshot

Activated CIK (Activated CIK) — Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.. Activated CIK (cytokine-induced killer cells) are ex vivo expanded immune cells that target and kill cancer cells through multiple mechanisms including natural killer and T-cell pathways.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Activated CIK TARGET	Activated CIK	Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.	phase 2	Adoptive cell therapy; ex vivo expanded immune cells
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19
Licartin and CIK	Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital	marketed	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
TIL + IL2	TIL + IL2	Nantes University Hospital	phase 3	Adoptive cell therapy; T cell immunotherapy	IL-2 receptor; tumor-associated antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adoptive cell therapy; ex vivo expanded immune cells class)

Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Activated CIK — Competitive Intelligence Brief. https://druglandscape.com/ci/activated-cik. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab